These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 17987036)

  • 1. Interleukin-6 trans signalling enhances photodynamic therapy by modulating cell cycling.
    Wei LH; Baumann H; Tracy E; Wang Y; Hutson A; Rose-John S; Henderson BW
    Br J Cancer; 2007 Dec; 97(11):1513-22. PubMed ID: 17987036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin-6-resistant melanoma cells exhibit reduced activation of STAT3 and lack of inhibition of cyclin E-associated kinase activity.
    Böhm M; Schulte U; Funk JO; Raghunath M; Behrmann I; Kortylewski M; Heinrich PC; Kues T; Luger TA; Schwarz T
    J Invest Dermatol; 2001 Jul; 117(1):132-40. PubMed ID: 11442760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of IL-6 trans-signaling in vascular leakage: implications for ovarian hyperstimulation syndrome in a murine model.
    Wei LH; Chou CH; Chen MW; Rose-John S; Kuo ML; Chen SU; Yang YS
    J Clin Endocrinol Metab; 2013 Mar; 98(3):E472-84. PubMed ID: 23348396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-alpha and IL-17.
    Hashizume M; Hayakawa N; Mihara M
    Rheumatology (Oxford); 2008 Nov; 47(11):1635-40. PubMed ID: 18786965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin-6 trans-signalling induces vascular endothelial growth factor synthesis partly via Janus kinases-STAT3 pathway in human mesothelial cells.
    Yang X; Lin A; Jiang N; Yan H; Ni Z; Qian J; Fang W
    Nephrology (Carlton); 2017 Feb; 22(2):150-158. PubMed ID: 26869278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble interleukin-6 receptor (sIL-6R) makes IL-6R negative T cell line respond to IL-6; it inhibits TNF production.
    Igaz P; Horváth A; Horváth B; Szalai C; Pállinger E; Rajnavölgyi E; Tóth S; Rose-John S; Falus A
    Immunol Lett; 2000 Mar; 71(3):143-8. PubMed ID: 10722865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Photodynamic therapy causes cross-linking of signal transducer and activator of transcription proteins and attenuation of interleukin-6 cytokine responsiveness in epithelial cells.
    Liu W; Oseroff AR; Baumann H
    Cancer Res; 2004 Sep; 64(18):6579-87. PubMed ID: 15374971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Essential roles of IL-6 trans-signaling in colonic epithelial cells, induced by the IL-6/soluble-IL-6 receptor derived from lamina propria macrophages, on the development of colitis-associated premalignant cancer in a murine model.
    Matsumoto S; Hara T; Mitsuyama K; Yamamoto M; Tsuruta O; Sata M; Scheller J; Rose-John S; Kado S; Takada T
    J Immunol; 2010 Feb; 184(3):1543-51. PubMed ID: 20042582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncostatin M and interleukin 6 inhibit cell cycle progression by prevention of p27kip1 degradation in HepG2 cells.
    Klausen P; Pedersen L; Jurlander J; Baumann H
    Oncogene; 2000 Jul; 19(32):3675-83. PubMed ID: 10951574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin-10 attenuates tumour growth by inhibiting interleukin-6/signal transducer and activator of transcription 3 signalling in myeloid-derived suppressor cells.
    Lee BR; Kwon BE; Hong EH; Shim A; Song JH; Kim HM; Chang SY; Kim YJ; Kweon MN; Youn JI; Ko HJ
    Cancer Lett; 2016 Oct; 381(1):156-64. PubMed ID: 27431309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-6 trans-signalling in chronic inflammation and cancer.
    Scheller J; Ohnesorge N; Rose-John S
    Scand J Immunol; 2006 May; 63(5):321-9. PubMed ID: 16640655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer.
    Rose-John S; Scheller J; Elson G; Jones SA
    J Leukoc Biol; 2006 Aug; 80(2):227-36. PubMed ID: 16707558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Humanised antihuman IL-6R antibody with interferon inhibits renal cell carcinoma cell growth in vitro and in vivo through suppressed SOCS3 expression.
    Oguro T; Ishibashi K; Sugino T; Hashimoto K; Tomita S; Takahashi N; Yanagida T; Haga N; Aikawa K; Suzutani T; Yamaguchi O; Kojima Y
    Eur J Cancer; 2013 May; 49(7):1715-24. PubMed ID: 23274199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin-6/soluble interleukin-6 receptor signaling attenuates proliferation and invasion, and induces morphological changes of a newly established pleomorphic malignant fibrous histiocytoma cell line.
    Nakanishi H; Yoshioka K; Joyama S; Araki N; Myoui A; Ishiguro S; Ueda T; Yoshikawa H; Itoh K
    Am J Pathol; 2004 Aug; 165(2):471-80. PubMed ID: 15277221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The classic signalling and trans-signalling of interleukin-6 are both injurious in podocyte under high glucose exposure.
    Lei CT; Su H; Ye C; Tang H; Gao P; Wan C; He FF; Wang YM; Zhang C
    J Cell Mol Med; 2018 Jan; 22(1):251-260. PubMed ID: 28881473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin-6 inhibits cell proliferation in a rat model of hepatocellular carcinoma.
    Moran DM; Mayes N; Koniaris LG; Cahill PA; McKillop IH
    Liver Int; 2005 Apr; 25(2):445-57. PubMed ID: 15780071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacologic IL-6Rα inhibition in cholangiocarcinoma promotes cancer cell growth and survival.
    Kleinegger F; Hofer E; Wodlej C; Golob-Schwarzl N; Birkl-Toeglhofer AM; Stallinger A; Petzold J; Orlova A; Krassnig S; Reihs R; Niedrist T; Mangge H; Park YN; Thalhammer M; Aigelsreiter A; Lax S; Garbers C; Fickert P; Rose-John S; Moriggl R; Rinner B; Haybaeck J
    Biochim Biophys Acta Mol Basis Dis; 2019 Feb; 1865(2):308-321. PubMed ID: 30419338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of interleukin-6 and soluble interleukin-6 receptors induces differentiation and activation of JAK-STAT and MAP kinase pathways in MG-63 human osteoblastic cells.
    Nishimura R; Moriyama K; Yasukawa K; Mundy GR; Yoneda T
    J Bone Miner Res; 1998 May; 13(5):777-85. PubMed ID: 9610741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The designer cytokine hyper-interleukin-6 is a potent activator of STAT3-dependent gene transcription in vivo and in vitro.
    Rakemann T; Niehof M; Kubicka S; Fischer M; Manns MP; Rose-John S; Trautwein C
    J Biol Chem; 1999 Jan; 274(3):1257-66. PubMed ID: 9880494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blocking interleukin-6 trans-signaling protects against renal fibrosis by suppressing STAT3 activation.
    Chen W; Yuan H; Cao W; Wang T; Chen W; Yu H; Fu Y; Jiang B; Zhou H; Guo H; Zhao X
    Theranostics; 2019; 9(14):3980-3991. PubMed ID: 31281526
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.